Status:
TERMINATED
A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
FoxHollow Technologies
Conditions:
Peripheral Vascular Diseases
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity...
Eligibility Criteria
Inclusion
- Participants with peripheral arterial disease
- Participants must be 18 to 85 years of age
- Females must be postmenopausal or sterile
Exclusion
- Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or uncontrolled hypertension
Key Trial Info
Start Date :
March 31 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 26 2008
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00679055
Start Date
March 31 2007
End Date
August 26 2008
Last Update
August 17 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.